Results 41 to 50 of about 304,289 (334)

Antibody neutralization of HIV-1

Immunology Today, 1996
Neutralizing antibodies are a major component of host defense against viruses, and appear to be particularly important in limiting the spread of cell-free virus. Results from vaccine trials in animal models suggest that these antibodies may contribute to protection against human immunodeficiency virus (HIV) infection.
Poignard, P, Klasse, P, Sattentau, Q
openaire   +2 more sources

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

RSV Neutralizing Antibodies in Dried Blood

The Journal of Infectious Diseases, 2023
Abstract Background The key correlate of protection of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies (mAbs) is virus neutralization, measured via sera obtained through venipuncture.
Jonne Terstappen, Eveline M Delemarre, Anouk Versnel, Joleen T White, Alexandrine Derrien-Colemyn, Tracy J Ruckwardt, Louis J Bont, Natalie I Mazur   +7 more
openaire   +3 more sources

Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts

Translational Oncology, 2017
Chemokines are small soluble molecules that play critical roles in wound healing, infection, and cancer progression. In particular, overexpression of the C-C motif chemokine ligand 2 (CCL2) in multiple cancer types correlates with poor patient prognosis.
Min Yao, Curtis Smart, Qingting Hu, Nikki Cheng   +3 more
doaj   +1 more source

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein [PDF]

, 2014
Infections with human respiratory syncytial virus (HRSV) occur globally in all age groups and can have devastating consequences in young infants. We demonstrate that a vaccine based on the extracellular domain (SHe) of the small hydrophobic (SH) protein ...
Bert Schepens, Brian Gilbert, Cherrie AH, Connors M, Glezen WP, Kenny Roose, Koen Sedeyn, Liesbeth Vande Ginste, Lieselot Houspie, Marc Van Ranst, Michael Schotsaert, Mills JT, Nicholas JA, Nico Rooijen, Olmsted RA, Pedro Piedra, Sarah De Baets, Ventre K, Walter Fiers, Whitehead SS, Xavier Saelens   +20 more
core   +3 more sources

BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study

Vaccines, 2023
This study aimed to analyze the dynamics, duration, and production of total and neutralizing antibodies induced by the BNT162b2 vaccine and the possible effect of gender and prior SARS-CoV-2 infection on the generation of these antibodies.
Jorge Hernández-Bello, José Julio Sierra-García-de-Quevedo, José Javier Morales-Núñez, Guillermo Santoscoy-Ascencio, Saúl Alberto Díaz-Pérez, Jesús Alberto Gutiérrez-Brito, José Francisco Muñoz-Valle   +6 more
doaj   +1 more source

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies [PDF]

, 2012
Lentiviral vectors (LVs) are potent gene transfer vehicles frequently applied in research and recently also in clinical trials. Retargeting LV entry to cell types of interest is a key issue to improve gene transfer safety and efficacy.
Abel, Tobias, Brynza, Julia, Buchholz, Christian J., Kneissl, Sabrina, Rasbach, Anke, Schneider-Schaulies, Jürgen   +5 more
core   +3 more sources

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Neutralizing antiviral antibody responses

, 2001
Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distinguish between virus serotypes; (2) B cell reactivity ...
Zinkernagel, R, LaMarre, A, Ciurea, A, Hunziker, L, Ochsenbein, A, McCoy, K, Fehr, T, Bachmann, M, Kalinke, U, Hengartner, H   +9 more
openaire   +3 more sources

Defining criteria for broadly neutralizing HIV antibodies

Frontiers in Immunology
Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses.
Elizabeth-Sharon David-Fung, Katherine A. Belobrajdic, Jennifer P. Macke, Corey R. Quackenbush, Kumkum Ganguly, Jennifer L. Mamrosh   +5 more
doaj   +1 more source